Norway, Nov. 20 -- Thor Medical ASA has signed a five-year frame agreement to supply NucliThera AS with thorium-228 (Th-228). The isotope will be used in NucliThera's development programs for hematological cancers. Led by Dr. Roy H. Larsen and Professor Emeritus Oyvind S. Bruland, NucliThera's research team is advancing an early-stage development program targeting hematological cancers such as lymphoma and leukemia. Dr. Larsen and Professor Bruland were jointly leading the development of the only alpha-emitting cancer pharmaceutical that so far has been approved by FDA - Xofigo for metastasized prostate cancer. The thorium-228 will be supplied from AlphaOne, Thor Medical's first commercial-scale isotope production facility, on track to begi...